EP2091334A4 - Dendritic cell tumor injection therapy and related vaccine - Google Patents
Dendritic cell tumor injection therapy and related vaccineInfo
- Publication number
- EP2091334A4 EP2091334A4 EP07871309A EP07871309A EP2091334A4 EP 2091334 A4 EP2091334 A4 EP 2091334A4 EP 07871309 A EP07871309 A EP 07871309A EP 07871309 A EP07871309 A EP 07871309A EP 2091334 A4 EP2091334 A4 EP 2091334A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- dendritic cell
- cell tumor
- tumor injection
- injection therapy
- related vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000017815 Dendritic cell tumor Diseases 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85590506P | 2006-10-31 | 2006-10-31 | |
PCT/US2007/083161 WO2008063837A2 (en) | 2006-10-31 | 2007-10-31 | Dendritic cell tumor injection therapy and related vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2091334A2 EP2091334A2 (en) | 2009-08-26 |
EP2091334A4 true EP2091334A4 (en) | 2010-02-03 |
Family
ID=39430435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07871309A Withdrawn EP2091334A4 (en) | 2006-10-31 | 2007-10-31 | Dendritic cell tumor injection therapy and related vaccine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2091334A4 (en) |
JP (1) | JP2010508364A (en) |
WO (1) | WO2008063837A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
WO2014004809A2 (en) * | 2012-06-27 | 2014-01-03 | Hasumi International Research Foundation | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082806A1 (en) * | 2001-04-27 | 2003-05-01 | Xcyte Therapies, Inc. | Maturation of antigen-presenting cells using activated T cells |
US7745157B2 (en) * | 2003-02-21 | 2010-06-29 | University Of Maryland, Baltimore | Human lymphocyte medium adjuvant |
US20060216269A1 (en) * | 2004-09-17 | 2006-09-28 | Kenichiro Hasumi | Dendritic cell tumor injection (DCTI) therapy |
-
2007
- 2007-10-31 JP JP2009535441A patent/JP2010508364A/en active Pending
- 2007-10-31 WO PCT/US2007/083161 patent/WO2008063837A2/en active Application Filing
- 2007-10-31 EP EP07871309A patent/EP2091334A4/en not_active Withdrawn
Non-Patent Citations (8)
Title |
---|
HATFIELD P ET AL: "Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?", CLINICAL ONCOLOGY, W.B. SAUNDERS, vol. 17, no. 1, 1 February 2005 (2005-02-01), pages 1 - 11, XP004693844, ISSN: 0936-6555 * |
KATANO MITSUO ET AL: "Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 25, no. 6A, 1 November 2005 (2005-11-01), pages 3771 - 3776, XP009127019, ISSN: 0250-7005 * |
MANN DEAN L ET AL: "Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES SEP 2009, vol. 1174, September 2009 (2009-09-01), pages 41 - 50, XP002559589, ISSN: 1749-6632 * |
MORISAKI T ET AL: "COMBINED IMMUNOTHERAPY WITH INTRACAVITAL INJECTION OF ACTIVATED LYMPHOCYTES, MONOCYTE-DERIVED DENDRITIC CELLS AND LOW-DOSE OK-432 IN PATIENTS WITH MALIGNANT EFFUSION", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6A, 1 November 2003 (2003-11-01), pages 4459 - 4466, XP009063436, ISSN: 0250-7005 * |
MORISAKI TAKASHI ET AL: "Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.", HUMAN CELL : OFFICIAL JOURNAL OF HUMAN CELL RESEARCH SOCIETY DEC 2003, vol. 16, no. 4, December 2003 (2003-12-01), pages 175 - 182, XP009063515, ISSN: 0914-7470 * |
SATO TAKAMI ET AL: "Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: A new approach to cancer immunotherapy.", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 53, no. 1, January 2004 (2004-01-01), pages 53 - 61, XP002560230, ISSN: 0340-7004 * |
YANO YUTARO ET AL: "A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: Efficient maturation of DCs by co-culture with LAK cells in vitro", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 16, no. 1, 1 July 2006 (2006-07-01), pages 147 - 152, XP009127013 * |
YU BIN ET AL: "Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 1, 1 January 2003 (2003-01-01), pages 285 - 294, XP002425821, ISSN: 1078-0432 * |
Also Published As
Publication number | Publication date |
---|---|
EP2091334A2 (en) | 2009-08-26 |
WO2008063837A2 (en) | 2008-05-29 |
WO2008063837A3 (en) | 2008-09-18 |
WO2008063837A9 (en) | 2008-08-07 |
JP2010508364A (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201104497B (en) | Peptide therapeutic conjugates and uses thereof | |
EP2170363A4 (en) | Tissue specific peptide conjugates and methods | |
HK1146300A1 (en) | Engineered dendritic cells and uses for the treatment of cancer | |
EP2180873A4 (en) | Therapeutic dental composition and related methods | |
HK1159526A1 (en) | Composition comprising tumor associated peptides and a vaccine for treatment of glioblastoma and other cancers | |
HK1136822A1 (en) | Therapeutic compounds and their use in cancer | |
EP2300011A4 (en) | Therapeutic methods and compounds | |
PT2144633E (en) | A system for delivering therapeutic agents into living cells and cells nuclei | |
EP1793678A4 (en) | Dendritic cell tumor injection (dcti) therapy | |
EP2142254A4 (en) | Feedback-controlled method for delivering photodynamic therapy and related instrumentation | |
GB0819280D0 (en) | Imgaing and radiotherapy methods | |
HRP20181178T1 (en) | Anti-androgen peptides and uses thereof in cancer therapy | |
EP2328640A4 (en) | Medical injector with post-autoreconstitution dose setting and autoplunger drive | |
GB0908868D0 (en) | Depsipeptide and their therapeutic use | |
EP1871166A4 (en) | Cancer vaccines and therapeutic methods | |
GB2460181B (en) | Depsipeptides and their therapeutic use | |
EP2097085A4 (en) | Therapeutic materials and methods | |
EP2091334A4 (en) | Dendritic cell tumor injection therapy and related vaccine | |
EP2363468A4 (en) | Tumor antigen peptide and use thereof | |
IL197691A0 (en) | Mir-143 regulated genes and pathways as targets for therapeutic intervention | |
GB2460180B (en) | Depsipeptides and their therapeutic use | |
EP2234667A4 (en) | Therapy calculation and therapy delivery modes | |
GB0818663D0 (en) | Gene regulation and its use in therapy | |
GB0612258D0 (en) | Transcutaneous cancer therapeutic | |
GB0606703D0 (en) | Transcutaneous cancer therapeutic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090527 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100105 |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20100504 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140419 |